Selinexor (XPOVIO®)
Multiple Myeloma
Key Facts
About Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel cancer therapies. The company's core expertise lies in oral SINE (Selective Inhibitor of Nuclear Export) compounds that inhibit XPO1, a protein critical to cancer cell survival. With one approved product and multiple clinical-stage programs, Karyopharm is advancing treatments across various hematologic cancers and solid tumors, driven by a mission to improve the lives of patients with cancer.
View full company profileAbout Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel cancer therapies. The company's core expertise lies in oral SINE (Selective Inhibitor of Nuclear Export) compounds that inhibit XPO1, a protein critical to cancer cell survival. With one approved product and multiple clinical-stage programs, Karyopharm is advancing treatments across various hematologic cancers and solid tumors, driven by a mission to improve the lives of patients with cancer.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Darzalex (daratumumab) | Johnson & Johnson | Approved |
| JNJ-4528 (CAR-T) | Johnson & Johnson | Phase 3 |
| Elrexfio | Pfizer | Approved |
| Revlimid (lenalidomide) | Bristol Myers Squibb | Commercial |
| Abecma (idecabtagene) | Bristol Myers Squibb | Commercial |
| Blenrep (belantamab mafodotin) | GSK plc | Approved |
| ABBV-383 | AbbVie | Phase 1/2 |
| REGN5458 | Regeneron Pharmaceuticals | Phase 1/2 |
| Ninlaro (ixazomib) | Takeda Pharmaceutical | Commercial |
| Tecvayli (teclistamab) | Genmab | Approved |
| Talquetamab | Genmab | Phase 3 |
| Lenalidomide (Generic Revlimid) | Dr. Reddy's Laboratories | Approved |